search
Back to results

Groceries for Black Residents of Boston to Stop Hypertension Among Adults With Treated Hypertension (GoFreshRx)

Primary Purpose

Hypertension

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Dietitian-Assisted DASH groceries
Self-directed shopping
Sponsored by
Beth Israel Deaconess Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring hypertension, blood pressure, nutrition, diet, DASH, sodium, trial, dietitian, cholesterol

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

INCLUSION:

  • Self-reported/self-identified as Black or African American
  • Resting systolic blood pressure of 120 to <150 mm Hg and diastolic blood pressure <100 mm Hg
  • Active treatment with medications intended for hypertension treatment within the last 6 months at stable doses
  • Residence in communities identified as Boston area food deserts: Brighton, Chelsea, Dorchester, East Boston, Everett, Hyde Park, Jamaica Plain, Malden, Mattapan, Revere, Roslindale, Roxbury, or Winthrop
  • Able to receive home-delivered groceries or pick them up at a convenient location and willing to eat only the groceries provided over a 12-week period
  • Have access to refrigeration, cooking appliances, and Wi-Fi/cellular service
  • Have access to mobile device or computer to be able to conduct grocery orders via video conference or by phone
  • Willing and able to complete required measurement procedures

EXCLUSION:

Laboratory Exclusions:

  • Serum potassium ≥5.0 mmol/L or <3.5 mmol/L
  • Estimated glomerular filtration rate (eGFR) <30 mL/min per 1.73 m^2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
  • Hemoglobin A1c ≥6.5%

Medication Exclusions:

  • Unstable doses of medications that lower blood pressure or medications intended for hypertension treatment (including antihypertensives taken for non-hypertension purposes) within the last 6 months
  • Unstable doses (i.e. a change in the 2 months prior to screening or randomization) of the following:

    • Sodium-glucose co-transporter 2 (SGLT2) inhibitors
    • Stimulants
    • Inhaled or oral medications for asthma or chronic obstructive pulmonary disease (COPD)
    • Hormone replacement therapy or thyroid hormone
    • Weight-increasing psychotropic agents, including antipsychotic agents, lithium, and mirtazapine
  • Use of any of the following medications:

    • Potassium supplement, except if part of a multivitamin
    • Warfarin (Coumadin)
    • Chronic oral corticosteroid (intermittent use is okay)
    • Weight loss medications (including GLP-1 receptor agonists)
  • Unwillingness to keep same dose of vitamin, mineral, and botanical supplements
  • Any medication not compatible with participation as determined by the investigators

Physical Exclusions:

  • Systolic blood pressure ≥150 mm Hg or diastolic blood pressure ≥100 mm Hg
  • Body weight >420 pounds
  • Arm circumference >50cm
  • Weight loss or gain of >5.0% of body weight during prior 2 months

Medical History Exclusions:

  • Type 1 or Type 2 Diabetes defined as a hemoglobin A1c ≥6.5% or diabetes treatment
  • Active cardiovascular disease or any event in the prior 6 months, including coronary artery bypass grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA), myocardial infarction (MI), cerebrovascular accident (CVA), or congestive heart failure (CHF) exacerbation requiring hospital admission
  • Cancer diagnosis or treatment in the last 2 years (non-melanoma skin cancer or localized breast or prostate or bladder cancer not requiring systemic therapy is acceptable)
  • Active inflammatory bowel disease, bowel resection, malabsorptive syndrome, pancreatitis (episode within past year), or history of bariatric surgery
  • Pregnancy or lactation or planned pregnancy
  • Any emergency department (ED) visit for asthma or chronic obstructive pulmonary disease (COPD) in the last 6 months
  • Any other serious illness or condition not compatible with participation as determined by the investigators

Lifestyle and Other Exclusions:

  • Significant food allergies, preferences, intolerances, or dietary requirements that would interfere with diet adherence
  • Consumption of more than 14 alcoholic drinks per week or consumption of more than 6 drinks on one or more occasion per week
  • Active substance use disorder that would interfere with participation
  • Extreme food insecurity
  • Participation in or planning to start weight loss program
  • Current participation in another clinical trial that could interfere with the study protocol
  • Anticipated change in residence prior to the end of the study
  • Families with more than 5 adults at dinner time (children are considered to be half an adult)
  • Investigator discretion

Sites / Locations

  • Beth Israel Deaconess Medical Center - Clinical Research CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Dietitian-Assisted DASH groceries

Self-directed shopping (referent assignment)

Arm Description

Participants will order groceries sufficient to meet their caloric needs each week for 12 weeks with the assistance of a dietitian/nutrition interventionist. Groceries will be delivered to participants' homes or picked up at a convenient location. The dietitian/nutrition interventionist will provide brief educational content at the time of food delivery. Orders will be placed via phone or through virtual counseling sessions. During the remainder of the study (months 4-12), participants will be asked to apply what they learned without the provision of groceries.

Participants will receive a monthly stipend over a 3 month period and some basic information about healthy eating. The stipend is not restricted to foods. During the remainder of the study (months 4-12), participants will be asked to continue their typical shopping without the provision of the monthly stipend.

Outcomes

Primary Outcome Measures

Seated, office-based, systolic blood pressure (intervention phase)
In-person, measured with an automated oscillometric device that will perform 3 measurements.

Secondary Outcome Measures

Seated, office-based, systolic blood pressure (observation phase)
In-person, measured with an automated oscillometric device that will perform 3 measurements.
Seated, office-based, diastolic blood pressure (intervention & observation phases)
In-person, measured with an automated oscillometric device that will perform 3 measurements.
Ambulatory blood pressure monitoring: wake-time systolic and diastolic blood pressure (intervention & observation phases)
Ambulatory blood pressure monitoring with a mobile blood pressure device that will measure blood pressure over a 24-hour period.
Body Mass Index (BMI) (intervention & observation phases)
In-person, measurement based on height and weight. Height is measured via a stadiometer and weight is measured via calibrated scale.
24-hour urine potassium (intervention & observation phases)
Collected at home after a clinic void over a 24-hour period
24-hour urine sodium (intervention & observation phases)
Collected at home after a clinic void over a 24-hour period
Hemoglobin A1c (intervention & observation phases)
In-person blood collection; measure of glycemia over the preceding 3 months
Lipids (intervention & observation phases)
Measured in fasted serum specimens collected during phlebotomy. Includes total cholesterol, high density lipoprotein cholesterol, derived low density lipoprotein cholesterol, and triglycerides
Serum potassium (intervention & observation phases)
Measured in blood as part of a basic metabolic panel
Serum creatinine (intervention & observation phases)
Measured in blood as part of a basic metabolic panel
Daily intake of fat, fruits, and vegetables (intervention & observation phases)
Assessed via questionnaire in-person and via phone call; assessed via a validated food screener (Block et al; PMID: 10788730).
24-hour dietary recall (intervention & observation phases)
Assessed via questionnaire in-person using the Automated Self-Administered 24-Hour Dietary Recall (ASA24)

Full Information

First Posted
May 23, 2022
Last Updated
January 11, 2023
Sponsor
Beth Israel Deaconess Medical Center
Collaborators
National Institute on Minority Health and Health Disparities (NIMHD)
search

1. Study Identification

Unique Protocol Identification Number
NCT05393232
Brief Title
Groceries for Black Residents of Boston to Stop Hypertension Among Adults With Treated Hypertension
Acronym
GoFreshRx
Official Title
Effects of DASH Groceries on Blood Pressure in Black Residents of Urban Food Deserts With Treated Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 13, 2022 (Actual)
Primary Completion Date
April 2025 (Anticipated)
Study Completion Date
October 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beth Israel Deaconess Medical Center
Collaborators
National Institute on Minority Health and Health Disparities (NIMHD)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
GoFreshRx is a randomized trial, testing the effects of a home-delivered DASH-patterned grocery intervention on blood pressure in Black adults actively treated for hypertension, residing in Boston area urban food deserts.
Detailed Description
Hypertension affects over half of Black adults in the United States - more than any other group - and diet is a principal determinant of disparities in hypertension among Black adults. While the DASH diet is a proven strategy for lowering blood pressure in Black adults, diet disparities are increasing in urban food deserts due to poor access and the high costs of healthy foods. Our proposed clinical trial will randomize 150 Black adults, who are actively treated for hypertension and reside in Boston area urban food deserts to either: 12 weeks of dietitian-assisted, DASH grocery delivery via an online, virtual grocery store at an amount sufficient to replace all Calorie needs of each participant, allowing for some sharing with family members or Self-directed shopping with a monthly stipend over a 3-month period After the 12-week intervention phase, participants will undergo a 9-month observation phase. At 3-months after the intervention is complete the investigators will repeat in-person study assessments and perform qualitative interviews in a subset of the population to determine barriers and facilitators to intermediate-term maintenance of the intervention. At 9-months after the intervention, participants will participate in a phone visit designed to assess longer-term maintenance of the intervention.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
hypertension, blood pressure, nutrition, diet, DASH, sodium, trial, dietitian, cholesterol

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Individual level, parallel, randomized trial
Masking
InvestigatorOutcomes Assessor
Masking Description
Outcomes assessors will not know randomization assignment. Investigators will not know randomization assignment. Participants and the nutritionist/dietitian interventionist will need to know randomization assignment in order to carry out the intervention.
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Dietitian-Assisted DASH groceries
Arm Type
Experimental
Arm Description
Participants will order groceries sufficient to meet their caloric needs each week for 12 weeks with the assistance of a dietitian/nutrition interventionist. Groceries will be delivered to participants' homes or picked up at a convenient location. The dietitian/nutrition interventionist will provide brief educational content at the time of food delivery. Orders will be placed via phone or through virtual counseling sessions. During the remainder of the study (months 4-12), participants will be asked to apply what they learned without the provision of groceries.
Arm Title
Self-directed shopping (referent assignment)
Arm Type
Active Comparator
Arm Description
Participants will receive a monthly stipend over a 3 month period and some basic information about healthy eating. The stipend is not restricted to foods. During the remainder of the study (months 4-12), participants will be asked to continue their typical shopping without the provision of the monthly stipend.
Intervention Type
Behavioral
Intervention Name(s)
Dietitian-Assisted DASH groceries
Intervention Description
The DASH ("Dietary Approaches to Stop Hypertension"), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages. Intervention Phase: This intervention is a weekly, 12-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size. Observation Phase: For months 4-12 of the study, participants will be asked to continue following a DASH grocery shopping pattern without the provision of weekly groceries.
Intervention Type
Behavioral
Intervention Name(s)
Self-directed shopping
Intervention Description
Intervention Phase: Participants will receive some basic information on healthy eating and a monthly stipend at 4, 8, and 12-weeks of the intervention. Observation Phase: For months 4-12 of the study, participants will be asked to follow their typical shopping pattern without the provision of a monthly stipend.
Primary Outcome Measure Information:
Title
Seated, office-based, systolic blood pressure (intervention phase)
Description
In-person, measured with an automated oscillometric device that will perform 3 measurements.
Time Frame
Measured 3 months after randomization
Secondary Outcome Measure Information:
Title
Seated, office-based, systolic blood pressure (observation phase)
Description
In-person, measured with an automated oscillometric device that will perform 3 measurements.
Time Frame
Measured 6 months after randomization
Title
Seated, office-based, diastolic blood pressure (intervention & observation phases)
Description
In-person, measured with an automated oscillometric device that will perform 3 measurements.
Time Frame
Measured 3 and 6 months after randomization
Title
Ambulatory blood pressure monitoring: wake-time systolic and diastolic blood pressure (intervention & observation phases)
Description
Ambulatory blood pressure monitoring with a mobile blood pressure device that will measure blood pressure over a 24-hour period.
Time Frame
Measured 3 and 6 months after randomization
Title
Body Mass Index (BMI) (intervention & observation phases)
Description
In-person, measurement based on height and weight. Height is measured via a stadiometer and weight is measured via calibrated scale.
Time Frame
Measured 3 and 6 months after randomization
Title
24-hour urine potassium (intervention & observation phases)
Description
Collected at home after a clinic void over a 24-hour period
Time Frame
Measured 3 and 6 months after randomization
Title
24-hour urine sodium (intervention & observation phases)
Description
Collected at home after a clinic void over a 24-hour period
Time Frame
Measured 3 and 6 months after randomization
Title
Hemoglobin A1c (intervention & observation phases)
Description
In-person blood collection; measure of glycemia over the preceding 3 months
Time Frame
Measured 3 and 6 months after randomization
Title
Lipids (intervention & observation phases)
Description
Measured in fasted serum specimens collected during phlebotomy. Includes total cholesterol, high density lipoprotein cholesterol, derived low density lipoprotein cholesterol, and triglycerides
Time Frame
Measured 3 and 6 months after randomization
Title
Serum potassium (intervention & observation phases)
Description
Measured in blood as part of a basic metabolic panel
Time Frame
Measured 3 and 6 months after randomization
Title
Serum creatinine (intervention & observation phases)
Description
Measured in blood as part of a basic metabolic panel
Time Frame
Measured 3 and 6 months after randomization
Title
Daily intake of fat, fruits, and vegetables (intervention & observation phases)
Description
Assessed via questionnaire in-person and via phone call; assessed via a validated food screener (Block et al; PMID: 10788730).
Time Frame
Measured 3, 6, and 12 months after randomization
Title
24-hour dietary recall (intervention & observation phases)
Description
Assessed via questionnaire in-person using the Automated Self-Administered 24-Hour Dietary Recall (ASA24)
Time Frame
Measured 3 and 6 months after randomization
Other Pre-specified Outcome Measures:
Title
Qualitative Interviews
Description
The investigators will perform qualitative interviews in a subpopulation of both study assignments to assess for barriers and facilitators related to long-term maintenance of the intervention.
Time Frame
6 months after randomization
Title
Short Form 12 Item Health Survey (SF-12)
Description
Assessment of global health-related quality of life
Time Frame
Measured 3, 6, and 12 months after randomization
Title
Grocery shopping and dining habits
Description
This is a modified version of the interviewer-administered SHoPPER (Study of Household Purchasing Patterns, Eating, and Recreation) instrument (French et al; PMID: 30808311) with some modifications to assess grocery shopping, meal preparation, and dining behaviors and habits.
Time Frame
Measured 3, 6, and 12 months after randomization
Title
Perceived Stress Scale 4 (PSS-4)
Description
An instrument used to assess participants' feelings about stress
Time Frame
Measured 3, 6, and 12 months after randomization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
INCLUSION: Self-reported/self-identified as Black or African American Resting systolic blood pressure of 120 to <150 mm Hg and diastolic blood pressure <100 mm Hg Active treatment with medications intended for hypertension treatment within the last 6 months at stable doses Residence in communities identified as Boston area food deserts: Brighton, Chelsea, Dorchester, East Boston, Everett, Hyde Park, Jamaica Plain, Malden, Mattapan, Revere, Roslindale, Roxbury, or Winthrop Able to receive home-delivered groceries or pick them up at a convenient location and willing to eat only the groceries provided over a 12-week period Have access to refrigeration, cooking appliances, and Wi-Fi/cellular service Have access to mobile device or computer to be able to conduct grocery orders via video conference or by phone Willing and able to complete required measurement procedures EXCLUSION: Laboratory Exclusions: Serum potassium ≥5.0 mmol/L or <3.5 mmol/L Estimated glomerular filtration rate (eGFR) <30 mL/min per 1.73 m^2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation Hemoglobin A1c ≥6.5% Medication Exclusions: Unstable doses of medications that lower blood pressure or medications intended for hypertension treatment (including antihypertensives taken for non-hypertension purposes) within the last 6 months Unstable doses (i.e. a change in the 2 months prior to screening or randomization) of the following: Sodium-glucose co-transporter 2 (SGLT2) inhibitors Stimulants Inhaled or oral medications for asthma or chronic obstructive pulmonary disease (COPD) Hormone replacement therapy or thyroid hormone Weight-increasing psychotropic agents, including antipsychotic agents, lithium, and mirtazapine Use of any of the following medications: Potassium supplement, except if part of a multivitamin Warfarin (Coumadin) Chronic oral corticosteroid (intermittent use is okay) Weight loss medications (including GLP-1 receptor agonists) Unwillingness to keep same dose of vitamin, mineral, and botanical supplements Any medication not compatible with participation as determined by the investigators Physical Exclusions: Systolic blood pressure ≥150 mm Hg or diastolic blood pressure ≥100 mm Hg Body weight >420 pounds Arm circumference >50cm Weight loss or gain of >5.0% of body weight during prior 2 months Medical History Exclusions: Type 1 or Type 2 Diabetes defined as a hemoglobin A1c ≥6.5% or diabetes treatment Active cardiovascular disease or any event in the prior 6 months, including coronary artery bypass grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA), myocardial infarction (MI), cerebrovascular accident (CVA), or congestive heart failure (CHF) exacerbation requiring hospital admission Cancer diagnosis or treatment in the last 2 years (non-melanoma skin cancer or localized breast or prostate or bladder cancer not requiring systemic therapy is acceptable) Active inflammatory bowel disease, bowel resection, malabsorptive syndrome, pancreatitis (episode within past year), or history of bariatric surgery Pregnancy or lactation or planned pregnancy Any emergency department (ED) visit for asthma or chronic obstructive pulmonary disease (COPD) in the last 6 months Any other serious illness or condition not compatible with participation as determined by the investigators Lifestyle and Other Exclusions: Significant food allergies, preferences, intolerances, or dietary requirements that would interfere with diet adherence Consumption of more than 14 alcoholic drinks per week or consumption of more than 6 drinks on one or more occasion per week Active substance use disorder that would interfere with participation Extreme food insecurity Participation in or planning to start weight loss program Current participation in another clinical trial that could interfere with the study protocol Anticipated change in residence prior to the end of the study Families with more than 5 adults at dinner time (children are considered to be half an adult) Investigator discretion
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Stephen P Juraschek, MD, PhD
Phone
617-754-1416
Email
sjurasch@bidmc.harvard.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Ruth-Alma Turkson-Ocran, PhD, FNP
Email
rturkson@bidmc.harvard.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephen P Juraschek, MD, PhD
Organizational Affiliation
Beth Israel Deaconess Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beth Israel Deaconess Medical Center - Clinical Research Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marwa Elborki
Phone
617-903-7943
Email
gofresh@bidmc.org

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
This project is complementary to the GoFresh Study (funded by the American Heart Association) with the purpose of creating a pooled resource of the two trials for secondary data analysis. Participants will be informed of sharing planning during the informed consent process.
IPD Sharing Time Frame
6-12 months after the study is complete
IPD Sharing Access Criteria
Upon reasonable request to investigators.
Links:
URL
http://gofreshstudy.org
Description
Main trial website (shared with the GoFresh Trial)

Learn more about this trial

Groceries for Black Residents of Boston to Stop Hypertension Among Adults With Treated Hypertension

We'll reach out to this number within 24 hrs